Background: Drug development for ultra-rare diseases is challenging because small sample sizes and heterogeneous study populations hamper the ability of randomized, placebo-controlled trials with a single primary endpoint to demonstrate valid treatment effects. Methods: To overcome these challenges, a novel Blind Start design was utilized in a study of vestronidase alfa in mucopolysaccharidosis VII (Sly syndrome), an ultra-rare lysosomal disease, that demonstrates the strengths of this approach in a challenging drug-development setting. Twelve subjects were randomized to 1 of 4 blinded groups, each crossing over to active treatment in a blinded fashion at different timepoints with efficacy analysis comparing the last assessment before cross over to after 24 weeks of treatment. Study assessments included: Percentage change from baseline in urinary GAG (uGAG); a Multi-Domain Responder Index (MDRI) using prespecified minimal important differences (6-Minute Walk Test, Forced Vital Capacity, shoulder flexion, visual acuity, and Bruininks-Oseretsky Test of Motor Proficiency); fatigue as assessed by the Pediatric Quality of Life Inventory™ Multidimensional Fatigue Scale; and safety. Results: Vestronidase alfa treatment for 24 weeks significantly reduced uGAG excretion (dermatan sulfate: 64.8%, p < 0.0001). Most subjects (10/12) had a clinically meaningful improvement in at least one MDRI domain with an overall mean change ( ± SD) of +0.5 ( ± 0.8) at Treatment Week 24 (p = 0.0527). Exposureadjusted incidence rates of adverse events were similar between groups. Conclusions: The Blind Start study and MDRI design improve statistical power that enhances detection of a positive treatment effect in this rare heterogeneous disease and could be utilized for other ultra-rare diseases.
Introduction
Ultra-rare disease drug development is frequently more challenging than for conditions with greater prevalence. The standard randomized, placebo-controlled trial (RCT) is often unsuitable because loss of statistical power (due to small sample size and risk of imbalance between groups) reduces the likelihood of showing a valid treatment effect. Furthermore, including all available patients, often required in rare diseases, results in heterogeneous study populations in age and disease severity, making selecting a single endpoint to measure clinical response difficult.
Mucopolysaccharidosis VII (MPS VII or Sly syndrome) is a chronically debilitating and life-threatening multi-system ultra-rare genetic disease. MPS diseases are lysosomal storage disorders caused by deficiency of an enzyme involved in the stepwise degradation of glycosaminoglycans (GAGs). With an estimated global incidence of < 200 patients, advancement of human therapeutics for MPS VII has been stymied (research began in the early 1970's) by the disease's extreme rarity, phenotypic diversity, and the inability to identify a single, meaningful outcome measure to test clinical efficacy.
We report a novel approach used in development of vestronidase alfa (recombinant human β-glucuronidase or rhGUS), an enzyme replacement therapy (ERT) for MPS VII, that included a unique Phase 3 Blind Start study design with a variable placebo run-in period masking the start of vestronidase alfa, and allowing all subjects to be assessed for efficacy. Another unique feature was the use of a Multi-Domain Responder Index (MDRI) that allowed translation of multiple clinical measures into a combination responder endpoint assessed using minimally important difference (MID) thresholds without penalizing for non-assessable endpoints in a heterogeneous patient population. The Phase 3 study was designed based on prior MPS ERT programs in which placebo-crossover patients demonstrated treatment effect sizes that were comparable to that observed with active treatment in the placebocontrolled period [1] . The Blind Start design accommodated the extreme rarity of MPS VII (estimated prevalence < 1/1,000,000) [2], making efficient use of the limited number of subjects. The results are presented herein.
Methods

The Blind Start design
The study randomized 12 subjects to one of four blinded groups, each with a different timepoint to cross over to vestronidase alfa ( Fig. 1 ). In the design, all subjects contribute to the assessment of treatment effect and have a within-patient comparison, which can be more powerful in heterogeneous diseases. Data on placebo treatment are also obtained and the assessment of change during placebo treatment as well as the comparison after crossover to active treatment can provide additional support for the validity of results.
Randomization for current study
Subjects were randomized 1:1:1:1 to one of four treatment sequence groups (Group A, B, C or D; 3 subjects per group; Fig. 1 ) to either start treatment with 4 mg/kg vestronidase alfa (Group A), or placebo and cross over to 4 mg/kg vestronidase alfa at different pre-defined time points (Weeks 8, 16, and 24 for Groups B, C, and D, respectively). All groups received a minimum of 24 weeks of treatment.
Dosing protocol
Subjects were dosed every other week through Week 46. Study drug was administered every two weeks by slow IV infusion over a period of approximately 4 h. Subjects were pre-medicated (Approximately 30 to 60 min prior to each infusion with an appropriate dose of antihistamine medication [eg, cetirizine or loratadine]) prior to infusion. Each infusion began at a low rate of 2.5% of the study drug dose volume for 1 h, and if that was well tolerated by the subject, the rate increased to an amount equal to the 97.5% remaining volume divided by 3 h and remained at that rate until the infusion was complete approximately 3 h later.
Assessments and evaluations
Primary endpoint: urinary GAG (uGAG) excretion
Clinical evidence for uGAG as a relevant and important endpoint was based on extensive preclinical research [3] [4] [5] [6] [7] [8] [9] , clinical disease survey studies, and Phase 3 controlled studies of other ERTs [1, [10] [11] [12] [13] [14] [15] . These studies demonstrated that GAG levels in urine and tissues and lysosomal storage in animal models were correlated with disease severity and clinical outcomes and demonstrated the sensitivity of uGAG in identifying differences in clinical effect within therapeutic dose ranges.
The percentage change from baseline in uGAG (as measured by LC-MS/MS [liquid chromatography-mass spectrometry/mass spectrometry]) [16] at Treatment Week 24 was analyzed by a general estimating equation (GEE) model, including baseline value as a covariate and the week after active treatment as a fixed effect. For the analysis, uGAG responders were defined as subjects who reached ≥50% reduction from baseline in uGAG excretion on at least one visit during the first 24 weeks of active treatment.
The Multi-Domain Responder Index (MDRI)
The MDRI is a novel approach to combine independent, clinically important domain responses scored on a pre-specified MID for each endpoint ( Table 2 ). The combination of responses across different domains allowed assessment of vestronidase alfa effectiveness more broadly as not all subjects needed to complete all tests and could successfully be assessed on only some tests. Non assessable data did not hinder the results. The MDRI consisted of 6 clinical domains: 6-minute Walk Test (6MWT) [17] , Forced Vital Capacity (FVC) [11, 12] , shoulder flexion [1, 12, 18, 19] , visual acuity [20] [21] [22] , and Bruininks-Oseretsky Test of Motor Proficiency (BOT-2) (fine motor and gross motor) [23] , and provided assessments of vestronidase alfa efficacy across a spectrum of clinical morbidities commonly observed in MPS diseases. The MID for each variable was pre-defined based on literature reports and results of prior MPS studies (Table 2) . Each domain score (−1 for decline, 0 for no change, +1 for improvement) was calculated based on the MID and summed for the MDRI score by visit. For each missing domain (i.e., assessable but not performed) at 24-weeks post treatment, the domain score at 32-weeks post treatment, if available, was used for imputation. MDRI imputation was applied to 2 subjects; one subject had their 6MWT test result imputed and one subject had their 6MWT, FVC, should flexion, and BOT-2 fine and gross motor test results imputed. If the domain score at 32-weeks post treatment was missing, the domain score at 16-weeks post treatment, if available, was used. Non-assessable domains (e.g., 6MWT if unable to walk) were scored as 0 with no impact to the analysis. This analysis allowed for translation of meaningful clinical results into a measurable endpoint that could be assessed in a variable patient sample with no penalty for assessments that could not be completed due to age or disease complications. 2  4  6  8  10  12  14  16  18  20  22  24  26  28  30  32  34  36  38  40  42  44  46 
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